Fosamax Femur Fracture Lawsuit
Fosamax® femur fracture lawsuits continue against Merck & Co.

Fosamax, also known as a bisphosphonate drug, was designed to aid in strengthening bones in patients that have been diagnosed with osteoporosis. Osteoporosis is a chronic condition which causes the bones to become brittle, resulting in fractures. However, recent studies have shown that when taken for long periods of time (12 months or more) bisphosphonate drugs including Fosamax may cause atypical femur fractures. Patients claim that these femur fractures would occur while involved in ordinary activities such as walking or jogging. Some other side effects linked to the drug include osteonecrosis, or “dead jaw,” esophageal cancer, and atrial fibrillation.

Users of the drug Fosamax are currently in the process of filing lawsuits against drug maker Merck & Co. Allegations are being made that Fosamax causes atypical femur fractures when taken for a year or more.  Experts are convinced that Fosamax does in fact cause femur fractures since it is shown to slow down the rate at which the human body replaces old bones with new, causing micro fractures to eventually become major fractures.

On January 7 of 2008, the Food and Drug Administration (FDA) issued a medical advisory warning doctors and patients about the side effects of Fosamax use. Two years later, the FDA mandated new warning labels for all bisphosphonate drugs. Researchers who have studied bisphosphonates drugs say that Fosamax is shown to slow down the rate at which the human body replaces old bones with new, causing micro fractures to eventually become major fractures. This process, known as bone turnover suppression, is what causes the femur to fracture.

Those who have taken the drug continue to pursue compensation by filing Fosamax femur fracture lawsuits against Merck & Co. Victims accuse the drug company of failing to properly warn about the risks associated with long term use of Fosamax. Merck counters these accusations by stating that no results of the side effects were discovered in their clinical trials prior to releasing Fosamax.

The next case hearing against Merck & Co. is scheduled for February 2012.

 

 

 

Categories: 

About the Contributor


Related Posts